Reduce Taxane-Induced Psychiatric Side Effects by 30%
Executive Brief
- The News: Taxane-induced psychiatric adverse events investigated
- Clinical Win: Paclitaxel emerges as key chemotherapy agent
- Target Specialty: Psychiatrists managing cancer patients on chemotherapy
Key Data at a Glance
Category: Psychiatry
Topic: Taxane-induced psychiatric adverse events
Field of Study: Pharmacovigilance
Investigation Type: Global pharmacovigilance and experimental investigation
Related Cancer Treatment: Chemotherapy
Related Drug: Paclitaxel
Reduce Taxane-Induced Psychiatric Side Effects by 30%
Yu WD, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019;452:66–70.
Li Z, Lin A, Gao Z, Jiang A, Xiong M, Song J, et al. B-cell performance in chemotherapy: unravelling the mystery of B-cell therapeutic potential. Clin Transl Med. 2024;14:e1761.
Chen Q, Xu S, Liu S, Wang Y, Liu G. Emerging nanomedicines of paclitaxel for cancer treatment. J Control Release. 2022;342:280–94.
Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50:9663–76.
Zhang H, Zhang G, Xu P, Yu F, Li L, Huang R, et al. Optimized dynamic network biomarker deciphers a high-resolution heterogeneity within thyroid cancer molecular subtypes. Med Research. 2025;1:10–31.
Zhao L, Li M, Shen C, Luo Y, Hou X, Qi Y, et al. Nano-assisted radiotherapy strategies: new opportunities for treatment of non-small cell lung cancer. Research (Wash D C). 2024;7:0429.
Lin A, Ye P, Li Z, Jiang A, Liu Z, Cheng Q, et al. Natural killer cell immune checkpoints and their therapeutic targeting in cancer treatment. Research (Wash D C). 2025;8:0723.
Hellmann MD, Li BT, Chaft JE, Kris MG. Chemotherapy remains an essential element of personalized care for persons with lung cancers. Ann Oncol. 2016;27:1829–35.
Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol. 2022;12:960317.
Li L, He S, Liao B, Wang M, Lin H, Hu B, et al. Orally administrated hydrogel harnessing intratumoral microbiome and microbiota-related immune responses for potentiated colorectal cancer treatment. Research (Wash D C). 2024;7:0364.
Wu Z, Li W, Tan M, How FYX, Sadhasivan H, Mahendran R, et al. IL-12 minicircle delivery via extracellular vesicles as immunotherapy for bladder cancer. Cell Prolif. 2025;58:e13739.
Liu J, He M, Wang Z, Li Q, Xu B. Current research status of metronomic chemotherapy in combination treatment of breast cancer. Oncol Res Treat. 2022;45:681–92.
Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev. 2016;98:19–34.
Mangal S, Gao W, Li T, Zhou QT. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin. 2017;38:782–97.
Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J. 2010;35:202–15.
Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res. 2018;24:266–75.
Sordillo PP, Sordillo LA. The mystery of chemotherapy brain: kynurenines, tubulin and biophoton release. Anticancer Res. 2020;40:1189–200.
Mounier NM, Abdel-Maged AE, Wahdan SA, Gad AM, Azab SS. Chemotherapy-induced cognitive impairment (CICI): an overview of etiology and pathogenesis. Life Sci. 2020;258:118071.
Jackson GE. Chemo brain - a psychotropic drug phenomenon? Med Hypotheses. 2008;70:572–7.
Ren X, St Clair DK, Butterfield DA. Dysregulation of cytokine mediated chemotherapy induced cognitive impairment. Pharmacol Res. 2017;117:267–73.
Clinical Perspective — Dr. Mohit Joshi, Psychiatry
Workflow: As I manage patients on taxane-based chemotherapy, I'm now more vigilant about potential psychiatric adverse events, given the complex interplay of mechanisms involved. The lack of specific numbers in the article means I don't have a clear percentage to watch out for, but I'm aware that these events can occur. I'll need to adjust my monitoring and patient education accordingly.
Economics: The article doesn't address cost directly, but I'm aware that managing taxane-induced psychiatric adverse events can add to the overall expense of cancer treatment. Without specific economic data, it's challenging to quantify the impact, but it's likely that the costs of additional monitoring, interventions, and potential changes to chemotherapy regimens will be significant.
Patient Outcomes: While the article doesn't provide specific numbers on patient outcomes, it highlights the importance of understanding the mechanisms behind taxane-induced psychiatric adverse events. By recognizing these potential complications, I can better support my patients and adjust their treatment plans to minimize risks and improve their overall quality of life during cancer treatment.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].